In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole Triclabendazole Aldicarb Methiocarb Montelukast and Ziprasidone

摘要

Background: The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process. Although many drugs can be metabolized to sulfoxide and/or sulfone metabolites, seldom is known on the CYP in-hibition potential and/or the metabolic fate for such metabolites.